CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed Net Margin across 11 years of filings, most recently posting 895.73% for Q2 2026.

• In Q2 2026, Net Margin rose 2248510.0% year-over-year to 895.73%; the TTM figure through Jun 2026 stood at 3611.9% (down 227279.0% YoY), while the FY2025 annual figure was 17496.47%, down 1640313.0% from the prior year.
• Net Margin came in at 895.73% for Q2 2026 at CRISPR Therapeutics AG, up from 8431.48% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 29.13% in Q4 2023 to a low of 1880950.0% in Q4 2022.
• Average Net Margin over 5 years is 137929.62%, with a median of 15722.08% recorded in 2025.
• Year-over-year, Net Margin sank 187985497 bps in 2022 and jumped 188097913 bps in 2023.
• Over 5 years, Net Margin stood at 1880950.0% in 2022, then soared by 100 bps to 29.13% in 2023, then plunged by 860 bps to 221.38% in 2024, then plunged by 8429 bps to 18881.94% in 2025, then surged by 95 bps to 895.73% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 895.73% in Q2 2026, 8431.48% in Q1 2026, and 18881.94% in Q4 2025.